In this episode, Jullia and Tom explore phase 2b in clinical trials and why this stage plays such a decisive role in moving a programme towards phase 3.
In this episode, Jullia and Tom unpack ACR response criteria in rheumatoid arthritis trials and why these endpoints are more operationally demanding than they look on paper.
In this episode, Jullia and Tom explore therapeutic areas in clinical research, why they matter beyond a clinical label, and how they shape trial design and delivery.